Bayer Aktiengesellschaft (OTC: BAYR.Y)
Bayer Aktiengesellschaft Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Bayer Aktiengesellschaft Company Info
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.
News & Analysis
2 No-Brainer Stocks to Buy Right Now for Less than $30
Two big companies that are worth investing in have low share prices but big dividends.
The Top Healthcare Stocks to Buy With $100
Don't overlook these big-name foreign healthcare stocks.
3 Growth Stocks Poised for Huge Gains in 2023
These big pharmaceuticals are poised for back-to-back big years.
Investors Wish They Could Vote These 2 Healthcare CEOs Out
With immobile stock prices and a hangover of legal issues, these CEOs might be glad Wall Street doesn't operate like a democracy.
Bayer to Acquire a Lead Position in America's Gene Therapy Space
The $4 billion deal will give the company's presence in the gene therapy space a huge boost.
Better Buy: Biogen vs. Bayer
Bayer's recent weakness may not end anytime soon.
2 Top Pharma Stocks to Buy in October
Looking for value in the pharmaceuticals sector? These two stocks have you covered.
3 Intriguing Value Stocks That Could Make You Rich
Here are three unconventional stocks that are significantly cheaper than they look.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.